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Background
Since the early 1980's foetal malformations can be diag-
nosed by increasingly sophisticated ultrasound (US)
examinations. Long term developmental follow up has
not been reported.
Materials and methods
We will report the outcome for all 241 patients referred
over the past 25 years by tertiary level Obstetricians to our
Neurodevelopmental team to either explain the options
for treatment of their affected foetus or to provide progno-
sis for their determination to terminate the pregnancy or
carry to term. They include all patients in the cohort and
include the following diagnoses: Major brain malforma-
tions – 22, Hydrocephalus – 45, Syndromes – 3 and Mye-
lomeningocele (MM) – 171. All but one case with MM
were delivered by caesarean section birth before the rup-
ture of amniotic membranes. Analysis was by X2 or Fishers
Exact.
Results
We averaged 7 to 8 consults per year with a range of 1 to
18. The fetal ages ranged from 17 to 36 weeks. Foetuses
with MM 24 weeks gestational age (EGA) or older were
terminated less frequently 4 of 74 (4%) than those of less
than 24 weeks EGA, 8 of 41 (19.5%), P = 0.015. Termina-
tion rates for the same EGA groups with hydrocephalus
were 0% and 17%, an insignificant difference. Of the foe-
tuses with MM given a "unfavorable" prognosis – high
rate of mental retardation and "severe" disability, 21%
were terminated and 17% of those assessed as having suf-
ficient intellectual ability to become self sufficient, P = 0.5.
For all foetuses with MM the outcomes were: terminations
20%; still born 3%; severe Chiari II symptoms 2%; post-
natal motor level 2 levels higher than predicted from in
utero estimates 5%, 1 level 10%, equal 32%, and lower by
1 level 14%, 2 levels 9% and 3 levels 5% and ? = 25%. Sen-
sory levels were assessed postnally compared to the
patients' motor level at the same time as follows; sensory
level was higher by 3 levels = 2%, 2 levels = 17%, 1 level =
42 % and equal only in 39% with none lower than the
motor level. Functional level achieved by those old
enough to evaluate were as follows, Preschool and Kinder-
garten L3 and above 36% with L4 and below = 13%; grade
school = 28% and 52%, normal = 20% and 22%, mentally
deficient 16% and 13% respectively, P = 0.12. The L3 and
above group had 16% moderate and severely mentally
retarded (MR) and the L4 and below had mild and mod-
erate MR = 13%. For those foetuses with MM who sur-
vived to be older than 8 years of age, 11 of 15 (73%) with
a favourable prognosis were developing normally and 13
of 22 with an unfavourable prognosis, P = 0.7. The small
numbers in the hydrocephalus and brain anomalies
groups prevent statistical analysis.
Conclusion
Some parents in the USA carry the pregnancy to term
despite severe fetal diagnoses. We lack data about long
term outcome of anomalies with poor prognoses.
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